662 related articles for article (PubMed ID: 35529878)
21. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
23. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
24. Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.
Huang L; Lou N; Xie T; Tang L; Han X; Shi Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3259-3277. PubMed ID: 37458771
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
Zhang C; Zhang G; Sun N; Zhang Z; Zhang Z; Luo Y; Che Y; Xue Q; He J
EBioMedicine; 2020 Sep; 59():102959. PubMed ID: 32853987
[TBL] [Abstract][Full Text] [Related]
26. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy.
Zhang P; Zhang H; Tang J; Ren Q; Zhang J; Chi H; Xiong J; Gong X; Wang W; Lin H; Li J; Huang C
Aging (Albany NY); 2023 Oct; 15(19):10305-10329. PubMed ID: 37796202
[TBL] [Abstract][Full Text] [Related]
27. Identification of a coagulation-related signature correlated with immune infiltration and their prognostic implications in lung adenocarcinoma.
Yang S; Chen S; Zhao Y; Wu T; Wang Y; Li T; Fu L; Ye T; Hu YQ; Chen H
Thorac Cancer; 2023 Nov; 14(33):3295-3308. PubMed ID: 37795779
[TBL] [Abstract][Full Text] [Related]
28. A gene expression-based immune signature for lung adenocarcinoma prognosis.
Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F
Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
30. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
31. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
32. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
Sui P; Liu X; Zhong C; Sha Z
Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
[TBL] [Abstract][Full Text] [Related]
33. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
34. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
[TBL] [Abstract][Full Text] [Related]
35. Construction and analysis of a novel ferroptosis-related gene signature predicting prognosis in lung adenocarcinoma.
Zhou J; Wang X; Li Z; Jiang R
FEBS Open Bio; 2021 Nov; 11(11):3005-3018. PubMed ID: 34499810
[TBL] [Abstract][Full Text] [Related]
36. Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.
Yu Q; Zhao L; Yan XX; Li Y; Chen XY; Hu XH; Bu Q; Lv XP
World J Surg Oncol; 2022 Jun; 20(1):183. PubMed ID: 35668494
[TBL] [Abstract][Full Text] [Related]
37. Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.
Zhang S; Li M; Tan Y; Zhang J; Liu Y; Jiang W; Li X; Qi H; Tang L; Ji R; Zhao W; Gu Y; Qi L
J Mol Med (Berl); 2022 Dec; 100(12):1755-1769. PubMed ID: 36367565
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G
J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
